Loading market data...

Kyle Olney Warns Clarity Act, BRCA Weakening Could Drive Blockchain Talent From US

Kyle Olney Warns Clarity Act, BRCA Weakening Could Drive Blockchain Talent From US

Kyle Olney is warning that two pieces of US crypto legislation — the Clarity Act and any further weakening of the Blockchain Regulatory Certainty Act (BRCA) — could drive blockchain developers and investment out of the country. In remarks made this week, Olney argued the policies would undermine the United States' competitive edge in emerging tech sectors, a frank assessment that lands as Congress wrestles with competing crypto bills.

The Clarity Act concern

The Clarity Act has been pitched as a way to define when a digital asset is a security versus a commodity. But Olney, whose exact role wasn't specified in the warning, argued the bill's current language could backfire. Instead of bringing legal certainty, he said, it would create new barriers that push blockchain projects to friendlier jurisdictions. The message is blunt: if the US makes life harder for developers, they'll go elsewhere.

Weakening the BRCA

The BRCA was designed to exempt certain blockchain developers from state-level money transmitter licenses — a carve-out meant to keep small teams from drowning in regulatory paperwork. Olney warned that rolling back or weakening that protection would have the same effect: talent and capital would flee to countries with clearer, more permissive rules. He didn't name specific destinations, but the implication is clear — Canada, Singapore, the UAE, and parts of Europe already compete aggressively for blockchain startups.

What's actually at stake

The US has long been the dominant home for blockchain development, from Ethereum's early days to the rise of Solana and Avalanche. But that lead has been slipping. Every legislative misstep — or perceived misstep — gives other countries an opening. Olney's warning isn't new in its general shape; industry insiders have been saying similar things for years. What's notable is the timing. Both the Clarity Act and the BRCA are actively being debated, and the outcome isn't decided.

No specific counterproposal or alternative wording has been offered by Olney in these remarks. The next concrete step will be whether lawmakers incorporate feedback from developers and investors before marking up either bill. If they don't, the brain drain Olney describes could start to look less like a warning and more like a forecast.